The FDA approved Arrowhead’s (ARWR) plozasiran, with the drug name Redemplo, to reduce triglycerides in adults with familial chylomicronemia syndrome on November 18, according to a post to the agency’s website.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead trading halted, news pending
- REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?
- Arrowhead price target raised to $45 from $29 at Morgan Stanley
- Arrowhead Pharmaceuticals Advances Alzheimer’s Treatment with New Clinical Study
- Arrowhead Pharmaceuticals Advances Cholesterol Treatment with Phase 3 Study